Login to Your Account

'Love at First Sight'

Infinity Licenses PI3K Program From Intellikine in $489M Deal

By Trista Morrison

Friday, July 9, 2010
Infinity Pharmaceuticals Inc. signed a $488.5 million global licensing deal for Intellikine Inc.'s preclinical phosphoinositide-3 kinase (PI3K) delta and gamma inhibitors, including lead compound INK1197, an oral small molecule slated to begin clinical trials for inflammatory diseases in 2011. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription